Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease

Journal of Neurology

Volumn 261, Issue 7, 2014, Pages 1387-1397

  Herben Dekker, Meike ^a   Van Oostrom, Joost C H ^a,d   Roos, Raymund A C ^c   Jurgens, Caroline K ^c,e   Witjes Ané, Marie Noëlle W ^c,e   Kremer, Hubertus P H ^a   Leenders, Klaus L ^a   Spikman, Jacoba M ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RIJNSTATE HOSPITAL   (Netherlands)

^e MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

Biomarker; Glucose metabolism; Huntington's disease; Premanifest; Psychomotor speed

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BRAIN METABOLISM; CAUDATE NUCLEUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DIGIT SYMBOL SUBSTITUTION TEST; FEMALE; GLOBUS PALLIDUS; HUMAN; HUNTINGTON CHOREA; MALE; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOMOTOR ACTIVITY; PUTAMEN; STROOP TEST; UNIFIED HUNTINGTON DISEASE RATING SCALE; WECHSLER MEMORY SCALE; COGNITION DISORDERS; COHORT ANALYSIS; COMPLICATION; CORPUS STRIATUM; DIAGNOSTIC USE; DISEASE COURSE; GENETICS; HUNTINGTON DISEASE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PREDICTIVE VALUE; PSYCHOMOTOR DISORDERS; SCINTISCANNING;

ADULT; COGNITION DISORDERS; COHORT STUDIES; CORPUS STRIATUM; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PSYCHOMOTOR DISORDERS; STATISTICS, NONPARAMETRIC;

EID: 84904971105     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7350-7     Document Type: Article

References (38)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72(6):971-983
2. Kirkwood SC, Siemers E, Hodes ME, Conneally PM, Christian JC, Foroud T (2000) Subtle changes among presymptomatic carriers of the Huntington's disease gene. J Neurol Neurosurg Psychiatry 69(6):773
3. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I, Huntington Study Group (2001) Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 57(4):658-662
4. Biglan KM, Zhang Y, Long JD, Geschwind M, Kang GA, Killoran A, Lu W, McCusker E, Mills JA, Raymond LA, Testa C, Wojcieszek J, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group (2013) Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci 5:12. doi: 10.3389/fnagi.2013.00012
5. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4(4):398-403. doi: 10.1038/ng0893-398
6. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, Folstein S, Ross C, Franz M, Abbott M et al (1993) Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 4(4):387-392. doi: 10.1038/ng0893-387
7. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR, International Huntington's Disease Collaborative Group (2004) A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 65(4):267-277. doi: 10.1111/j.1399-0004.2004.00241.x
8. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2008) Detection of Huntington's disease decades before diagnosis: the PREDICT-HD study. J Neurol Neurosurg Psychiatry 79(8):874-880
9. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC, TRACK-HD investigators (2009) Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8(9):791-801. doi: 10.1016/S1474-4422(09)70170-X
10. Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Carlozzi N, Duff K, Beglinger LJ, Langbehn DR, Johnson SA, Biglan KM, Aylward EH (2011) Neurocognitive signs in prodromal Huntington disease. Neuropsychology 25(1):1-14. doi: 10.1037/a0020937
11. Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR, TRACK-HD investigators (2012) Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11(1):42-53. doi: 10.1016/S1474-4422(11)70263-0
12. Kuhl DE, Markham CH, Metter EJ, Riege WH, Phelps ME, Mazziotta JC (1985) Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease. Res Publ Assoc Res Nerv Ment Dis 63:199-209
13. Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, de Yébenez JG, Boesiger P, Weindl A, Maguire RP (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain J Neurol 119(6):2085-2095
14. 18F]FDG PET study. J Nucl Med 42(11):1591-1595
15. Van Oostrom JCH, Maguire RP, Verschuuren-Bemelmans CC, Veenma-van der Pruim J, Roos RAC, Leenders KL (2005) Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology 65(6):941-943
16. Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, Paulsen JS, Dhawan V, Eidelberg D (2007) Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain J Neurol 130(11):2858-2867
17. Paulsen JS (2009) Functional imaging in Huntington's disease. Exp Neurol 216(2):272-277. doi: 10.1016/j.expneurol.2008.12.015
18. Tang CC, Feigin A, Ma Y, Habeck C, Paulsen JS, Leenders KL, Teune LK, van Oostrom JCH, Guttman M, Dhawan V, Eidelberg D (2013) Metabolic network as a progression biomarker of premanifest Huntington's disease. J Clin Investig 123(9):4076-4088. doi: 10.1172/JCI69411
19. Van Oostrom JCH, Dekker M, Willemsen AT, De Jong BM, Roos RA, Leenders KL (2009) Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease. Eur J Neurol 16(2):226-231. doi: 10.1111/j.1468-1331.2008. 02390.x
20. Huntington Study Group (1996) Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 11(2):136-142
21. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189-198
22. Verhage F (1964) Intelligentie en leeftijd: Onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar (Proefschrift). Van Gorcum, Assen
23. Quinn N, Brown R, Craufurd D, Goldman S, Hodges J, Kieburtz K, Lindvall O, MacMillan J, Roos R (1996) Core assessment program for intracerebral transplantation in Huntington's disease (CAPIT-HD). Mov Disord 11(2):143-150
24. Stroop JR (1935) Studies of interference in serial verbal reactions. J Exp Psychol 18:643-662
25. Reitan RM (1958) Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 8:271-276
26. Smith A (1968) The symbol digit modalities test: a neuropsychologic test for economic screening of learning and other cerebral disorders. Learn Disord 3:83-91
27. Benton AL (1976) Multilingual aphasia examination. University of Iowa Press, Iowa City
28. Wechsler DA (1945) A standardized memory scale for clinical use. J Psychol 19:87-95
29. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6(2):65-70
30. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR, The TRACK-HD Investigators (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12(7):637-649. doi: 10.1016/S1474-4422(13)70088-7
31. Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ (1994) Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 44(5):823-828
32. Wolf RC, Vasic N, Schönfeldt-Lecuona C, Landwehrmeyer GB, Ecker D (2007) Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. Brain nov 130(Pt 11):2845-2857 Epub 2007 sep 13
33. Harrington DL, Smith MM, Zhang Y, Carlozzi NE, Paulsen JS, The PREDICT-HD Investigators of the Huntington Study Group (2012) Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 83:612-619. doi: 10.1136/jnnp-2011-301732
34. Campodonico JR, Aylward E, Codori A, Yound C, Krafft L, Magdalinski M, Ranen N, Slavney PR, Brandt J (1998) When does Huntington's disease begin? J Int Neuropsychol Soc 4:467-473
35. Jurgens CK, van de Wiel L, van Es A, Grimbergen YM, Witjes-Ané MN, van der Grond J, Middelkoop HA, Roos RA (2008) Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease. J Neurol 255(11):1785-1791. doi: 10.1007/s00415-008-0050-4
36. Snowden JS, Craufurd D, Thompson J, Neary D (2002) Psychomotor, executive, and memory function in preclinical Huntington's disease. Neuropsychol Dev Cognit Sect A 24(2):133
37. Stout JC, Jones R, Labuschagne I, O'Regan AM, Say MJ, Dumas EM, Queller S, Justo D, Santos RD, Coleman A, Hart EP, Dürr A, Leavitt BR, Roos RA, Langbehn DR, Tabrizi SJ, Frost C (2012) Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J Neurol Neurosurg Psychiatry 83(7):687-694. doi: 10.1136/jnnp-2011-301940
38. Witjes-Ané MN, Mertens B, van Vugt JP, Bachoud-Lévi AC, van Ommen G, Roos RA (2007) Longitudinal evaluation of "presymptomatic" carriers of Huntington's disease. J Neuropsychiatry Clin Neurosci 19(3):310-317